Who
Jeffrey S. Heier
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, Ocular Therapeutix.
In numbers
- Trades disclosed
- 34
- Buys
- 2
- Sells
- 10
- Bought
- $145K
- Sold
- $512K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 11 Sep 2015
- Last trade
- 2 Oct 2026
- Last filed
- 6 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Oct 2026filed 6 Oct 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $77K10,869 at $7.05 | filing |
| 24 Aug 2026filed 26 Aug 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $36K3,296 at $10.78 | filing |
| 24 Aug 2026filed 26 Aug 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $36K3,296 at $10.78 | filing |
| 26 May 2026filed 28 May 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $25K3,018 at $8.20 | filing |
| 26 May 2026filed 28 May 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $25K3,018 at $8.20 | filing |
| 23 Feb 2026filed 25 Feb 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $25K3,057 at $8.28 | filing |
| 23 Feb 2026filed 25 Feb 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $25K3,057 at $8.28 | filing |
| 2 Jan 2026filed 6 Jan 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —79,112 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —240,932 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —240,932 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —79,112 at $0.00 | filing |
| 24 Nov 2025filed 26 Nov 2025 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $42K3,469 at $12.04 | filing |
| 2 Oct 2025filed 6 Oct 2025 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $116K10,502 at $11.04 | filing |
| 25 Aug 2025filed 27 Aug 2025 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $37K3,063 at $12.04 | filing |
| 23 May 2025filed 27 May 2025 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $22K3,024 at $7.18 | filing |
| 24 Feb 2025filed 26 Feb 2025 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $21K3,061 at $6.87 | filing |
| 25 Nov 2024filed 27 Nov 2024 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Sold | $27K2,948 at $9.01 | filing |
| 2 Oct 2024filed 4 Oct 2024 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 2 Oct 2024filed 4 Oct 2024 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 2 Aug 2023filed 18 Aug 2023 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,350 at $0.00 | filing |
News
Ocular Therapeutix (NASDAQ:OCUL) Stock: Insider Todd Anderman Sells 11,984 SharesOCUL · themarketsdaily.com · 15 Oct 2026Ocular Therapeutix (NASDAQ:OCUL) Upgraded to Strong-Buy at UBS GroupOCUL · dailypolitical.com · 14 Oct 2026Contrasting Ocular Therapeutix (NASDAQ:OCUL) and Bausch Health Cos (NYSE:BHC)OCUL · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Jeffrey S. Heier; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.